A detailed history of Voya Investment Management LLC transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 13,122 shares of GLUE stock, worth $111,405. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,122
Previous 11,153 17.65%
Holding current value
$111,405
Previous $41,000 68.29%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.59 - $6.97 $7,068 - $13,723
1,969 Added 17.65%
13,122 $69,000
Q2 2024

Aug 14, 2024

BUY
$3.38 - $7.86 $2,011 - $4,676
595 Added 5.64%
11,153 $41,000
Q1 2024

May 15, 2024

SELL
$4.26 - $8.46 $8,123 - $16,133
-1,907 Reduced 15.3%
10,558 $74,000
Q4 2023

Feb 14, 2024

SELL
$2.5 - $5.93 $200,912 - $476,564
-80,365 Reduced 86.57%
12,465 $70,000
Q2 2023

Aug 14, 2023

BUY
$4.53 - $8.4 $2,274 - $4,216
502 Added 0.54%
92,830 $635,000
Q4 2022

Feb 14, 2023

SELL
$6.71 - $9.72 $46,124 - $66,815
-6,874 Reduced 6.93%
92,328 $702,000
Q3 2022

Mar 03, 2023

BUY
$7.17 - $12.16 $49,286 - $83,587
6,874 Added 7.45%
99,202 $810,000
Q3 2022

Nov 14, 2022

BUY
$7.17 - $12.16 $636,495 - $1.08 Million
88,772 Added 851.12%
99,202 $811,000
Q2 2022

Aug 15, 2022

BUY
$6.15 - $14.99 $64,144 - $156,345
10,430 New
10,430 $101,000
Q1 2022

May 16, 2022

SELL
$10.36 - $20.41 $987,877 - $1.95 Million
-95,355 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$16.28 - $27.15 $121,546 - $202,701
-7,466 Reduced 7.26%
95,355 $1.95 Million
Q3 2021

Nov 15, 2021

SELL
$18.59 - $42.21 $25,208 - $57,236
-1,356 Reduced 1.3%
102,821 $2.29 Million
Q2 2021

Aug 16, 2021

BUY
$18.86 - $22.7 $1.96 Million - $2.36 Million
104,177 New
104,177 $2.36 Million

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $397M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.